DMRA

Damora Therapeutics, Inc. Common Stock
DMRA

Upgrade to unlock
Buy
Hold
Sell

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
Avg. target
$44
66% upside
High target

3 analyst ratings

positive
0  neutral
0%
negative
Analyst & Firm Rating Price Target Upside
Downside 		Date
UBS
UBS
Michael Yee
0% 1-yr DMRA win rate
17 Feb ‘26 23 days ago
Guggenheim
Guggenheim
Bradley Canino
67% 1-yr DMRA win rate
17 Feb ‘26 23 days ago
Leerink Partners
Leerink Partners
Andrew Berens
100% 1-yr DMRA win rate
7 Jan ‘26 2 months ago